Capstone Investment Advisors
HOWL icon

Capstone Investment Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Capstone Investment Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$174K – 2027
2021
Q2 		$174K Buy
+10,000
New +$137K ﹤0.01% 1519

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Capstone Investment Advisors's HOWL Position: Q3 2021 in Review

Capstone Investment Advisors sold out of Werewolf Therapeutics (HOWL) in Q3 2021, closing a stake of 10,000 shares — an estimated $174K sold.

Capstone Investment Advisors first reported a position in HOWL in Q2 2021 and held it in 1 quarter. The position peaked at $174K in Q2 2021. 42 funds tracked by Wall St. Rank hold HOWL as of Q3 2021.

  • Capstone Investment Advisors reported no remaining Werewolf Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 10,000 Werewolf Therapeutics shares in Q3 2021, an estimated $174K.
  • Capstone Investment Advisors first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Werewolf Therapeutics position peaked at $174K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2021.

Based on Capstone Investment Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.